載入...
A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer
PURPOSE: To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colo...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2008
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3086427/ https://ncbi.nlm.nih.gov/pubmed/18765554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0433 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|